UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  October 17, 2017
AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
000-50761
11-3146460
(State or Other Jurisdiction
of Incorporation)
(Commission File
Number)
(IRS Employer
Identification No.)
 
 14 Plaza Drive Latham, New York                       12110
  
(Address of Principal Executive Offices)               (Zip Code)
  
 
(518) 795-1400
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 – Submission of Matters to a Vote of Security Holders.

(a)
The Annual Meeting of Shareholders of AngioDynamics, Inc. (“AngioDynamics”) was held on October 17, 2017.
   
(b)
Shareholders voted on the matters set forth below.

1.
The nominees for election to the Board of Directors were elected, each as a Class II director to serve until the 2020 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes:

 
Nominee
Votes For
Withheld
Broker Non Votes
 
Eileen O. Auen
30,581,280
492,986
2,217,882
 
James C. Clemmer
30,500,873
573,393
2,217,882
 
Howard W. Donnelly
30,451,097
623,169
2,217,882
 
Jan Stern Reed
30,581,348
492,918
2,217,882

2.
The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2018 was approved based upon the following votes:
 
 
Votes for approval
33,069,290
 
Votes against
29,597
 
Abstentions
193,261
  There were no broker non-votes for this item.  
 
3.
The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation of its named executive officers was approved based upon the following votes:

 
Votes for approval
30,253,432
 
Votes against
720,710
 
Abstentions
100,124
 
Broker non vtes
2,217,882

4.
The proposal on the frequency of future advisory votes on executive compensation received the following votes:

 
For 3 Years
7,156,014
 
For 2 Years
14,153
 
For 1 Year
23,804,430
 
Abstentions
99,669
 
Broker-Non Votes
2,217,882
 
See Item 5.07(d) below.
  
 
 
(c)
Not applicable.
   
(d)
Based upon the results set forth in item (b) (4) above, the Board of Directors has determined that advisory votes on executive compensation will be submitted to shareholders on an annual basis.
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
ANGIODYNAMICS, INC.
(Registrant)
  
       
Date: October 20, 2017
By:
/s/ Stephen A. Trowbridge  
    Stephen A. Trowbridge  
    Senior Vice President and  
    General Counsel